gynokadin® Dosiergel


Gynokadin Spender

gynokadin® Dosiergel

Gel zur äußerlichen Anwendung auf der Haut
Wirkstoff: 0,6 mg Estradiol/g Gel (0,06%)

Download Beipackzettel

Download Fachinformation

 

Geschützter Bereich

Liebe Besucherin, lieber Besucher,

aufgrund von Bestimmungen des Heilmittelwerbegesetzes sind wir verpflichtet, bestimmte Inhalte nur Fachkreisen zugänglich zu machen. Sie sind daher mit einem DocCheck-Login passwortgeschützt.

Anmeldung DocCheck

Sie sind bereits registriert? Dann können Sie sich mit Ihrem Username und Passwort einloggen.

Sie besitzen noch keinen Account bei DocCheck? Hier können Sie sich schnell und unkompliziert registrieren.

  • 1.

    Kuhl H. (1998). Pharmakologie von Sexualsteroiden. Gynäkologe; 31:832-847.

  • 2.

    Mohammed, K., et al. (2015, Nov). Oral vs Transdermal Estrogen Therapy and Vascular Events: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab, 100(11), pp. 4012-20.

  • 3.

    Olie V, et al. (2011). Hormone therapy and recurrence of venous thromboembolism among postmenopausal women. Menopause;18(5):488-493.

  • 4.

    Renoux, C., Dell'aniello, S., Garbe, E., Suissa, S. (2010, Jun). Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ, 340, p. c2519.

  • 5.

    Canonico, M., et al. (2016, Jul). Postmenopausal Hormone Therapy and Risk of Stroke: Impact of the Route of Estrogen Administration and Type of Progestogen. Stroke, 47(7), pp. 1734-41.

  • 6.

    Lokkegaard E, Nielsen LH, Keiding N. (2017). Risk of Stroke With Various Types of Menopausal Hormone Therapies: A National Cohort Study. Stroke;48(8):2266-2269.

  • 7.

    Canonico, M., et al. (2006, Jun). Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The ESTHER Study. J Thromb Haemost, 4(6), pp. 1259-65.

  • 8.

    Liu, B, et al., (2008, Jul). Gallbladder disease and use of transdermal versus oral hormone replacement therapy in postmenopausal women: prospective cohort study. BMJ. Vol. 337, p. a386. Gynäkologie, Menopause.

  • 9.

    Racine, A., et al. (2013, Apr). Menopausal hormone therapy and risk of cholecystectomy: a prospective study based on the French E3N cohort. CMAJ, 185(7), pp. 555-61.

  • 10.

    Fournier, A., et al. (2014, Jun). Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort. Breast Cancer Res Treat, 145(2), pp. 535-43.

  • 11.

    Cordina-Duverger, E., et al. (2013, Nov). Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France. PLoS One, 8(11), p. e78016.

  • 12.

    Canonico, M., et al. (2007, Feb). Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation, 115(7), pp. 840-5.

  • 13.

    Canonico, M., et al. (2010, Feb). Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol, 30(2), pp. 340-5.